Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : AKE-1018
Therapeutic Area : Neurology
Study Phase : Preclinical
Sponsor : Weill Cornell Medicine
Deal Size : Inapplicable
Deal Type : Inapplicable
Akelos Inc.'s Lead Compound Achieves Preclinical Safety Milestone
Details : Akelos's oral lead compound AKE-1018, at 10-times the lowest effective antihyperalgesic dose tested, does not affect heart rate, blood pressure, motor strength/coordination, is non-sedating, and lacks the potential for abuse.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 03, 2021
Lead Product(s) : AKE-1018
Therapeutic Area : Neurology
Highest Development Status : Preclinical
Sponsor : Weill Cornell Medicine
Deal Size : Inapplicable
Deal Type : Inapplicable